Partial Response in an RRx-001-Primed Patient with Refractory Small-Cell Lung Cancer after a Third Introduction of Platinum Doublets

Partial Response in an RRx-001-Primed Patient with Refractory Small-Cell Lung Cancer after a Third Introduction of Platinum Doublets

Blog Article

Small-cell lung cancer (SCLC), initially exquisitely sensitive to first-line cisplatin/etoposide, invariably relapses and acquires a multidrug chemoresistant phenotype that generally renders retreatment with first-line therapy both futile and counterproductive.This report presents the case of a 77-year-old Caucasian male with extensive-stage refractory SCLC who was iphone 13 pro max price florida restarted on platinum doublets as part of a clinical trial called TRIPLE THREAT (NCT02489903) involving pomyslnaszycie.com pretreatment with the epi-immunotherapeutic agent RRx-001, and who achieved a partial response after only 4 cycles.The patient had received a platinum drug twice before, in 2009 for a diagnosis of non-small-cell lung cancer (squamous cell carcinoma) and in 2015 for SCLC, suggesting that RRx-001 pretreatment may sensitize or resensitize refractory SCLC patients to first-line chemotherapy.